LATEST NEWS
December 23, 2022 | Company Announcements
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus VaccineDecember 08, 2022 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 17, 2022 | Company Announcements
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox VaccinesNovember 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2022October 17, 2022 | Company Announcements
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial September 20, 2022 | Company Announcements
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic September 20, 2022 | Company Announcements
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to CanadaSeptember 07, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseSeptember 07, 2022 | Company Announcements
Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA)